Logo

Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Share this
Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Shots:

  • The P-II TANGO study evaluating the safety & efficacy of gosuranemab vs PBO in 654 patients aged 50–80 yrs with MCI due to AD or with mild AD for 78 wks across 97 sites- followed by a dose-blind long term extension period
  • The trial did not meet its 1EPs i.e change from baseline on CDR-SB @ 78 wks.- no treatment benefit was observed on exploratory efficacy EPs includes ADAS-Cog 13- ADCS-ADL- MMSE & FAQ. Additionally- the therapy was well-tolerated overall & safety outcomes were consistent with previous studies of gosuranemab
  • The company has decided to discontinue the further clinical development of gosuranemab while investigation of additional data include CSF biomarkers are ongoing

  | Ref: Globe Newswire | Image:Biogen

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions